Senate FDA bill clears committee, would modify regulatory framework for lab developed tests Â
The Senate Health, Education, Labor & Pensions Committee last night voted 13-9 that would reauthorize Food and Drug Administration user fee programs and modify the regulatory framework for laboratory developed tests. AHA last week urged lawmakers to consider certain changes to the LDT provisions to ensure continued access to these critical tests.
The House last week passed its own bill (H.R. 7667) to reauthorize FDA user fee programs, which does not include the LDT provisions. Among other provisions, the House bill would include drugs on the FDA’s shortages list in a pilot program to designate advanced manufacturing technologies.
Related News Articles
Headline
The AHA June 16 released a fact sheet with analysis on the impact to rural patients and hospitals from proposed Medicaid cuts by Congress. The analysis found…
Headline
Data from the Cecil G. Sheps Center for Health Services Research at the University of North Carolina at Chapel Hill shows that health care cuts under…
Headline
The House June 4 passed the AHA-supported SUPPORT Act (H.R. 2483) by a 366-57 vote. The legislation reauthorizes key prevention, treatment and recovery…
Headline
Sens. Chuck Schumer, D-N.Y., Susan Collins, R-Maine, and Andy Kim, D-N.J., June 5 reintroduced the SEPSIS Act, legislation which would task the Centers for…
Perspective
As Reconciliation Bill Shifts to the Senate, We Must Speak Up to Protect Medicaid and Access to Care
After approval in the House last week by a one vote margin, the One Big Beautiful Bill Act — a sweeping package that would enact many of President Trump’s…
Headline
The House Energy and Commerce Committee today advanced by a 30-24 vote along party lines its portion of the fiscal year 2025 reconciliation bill following a…